News

Treatment with Uplizna (inebilizumab-cdon) was associated with fewer attacks and reduced disability in Chinese adults with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) antibodies, a real-world study found. The estimated one-year attack-free rate was 95.5%. According to the researchers, the findings “provided evidence on the real-world…

MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo at preventing relapses and controlling disease activity in people with the autoimmune disease. That’s according to data from the Phase 3 portion of a China-based Phase 1b/3 clinical trial…

Immunosuppressive treatments can reduce the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who test negative for known disease-driving antibodies, a review study showed. Because relapses in these patients often lead to permanent disability, the findings suggest that immunosuppressive treatment should be given early to…

Researchers have identified a mechanism by which the adult brain can replace astrocytes, the neuron-supporting cells in the brain that are attacked and lost in people with neuromyelitis optica spectrum disorder (NMOSD). Using mice with NMOSD-like disease, the researchers found that surviving astrocytes around lesions will replicate their DNA…

A global clinical trial testing Ultomiris (ravulizumab-cwvz) in adults with neuromyelitis optica spectrum disorder (NMOSD) found that the treatment kept patients free of relapses for more than 4.5 years. When compared with data from an external group of NMOSD patients given a placebo in a previous trial, the…

Children with neuromyelitis optica spectrum disorder (NMOSD) are more likely to have severe vision problems and incomplete visual recovery than those with the related condition myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). That’s according to a review of published studies involving children with NMOSD associated with antibodies against the aquaporin-4…

Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab), two approved treatments for neuromyelitis optica spectrum disorder (NMOSD), may work better than rituximab — a drug not cleared for treating the autoimmune disease but often used off-label — for preventing NMOSD relapses, according to a new review. Still, the study findings…

A specialized MRI measure used as a proxy of the brain’s waste-clearing system may help monitor disease severity and progression in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new study. NMOSD patients had significantly lower values of the imaging marker, called diffusion tensor imaging (DTI) analysis along…

A short-course of Soliris (eculizumab) treatment during relapses may help people with neuromyelitis optica spectrum disorder (NMOSD) recover faster when standard therapies fail, a small study in China suggests. Patients who saw little or no improvement after corticosteroids, with or without plasma exchange, experienced meaningful gains in mobility…

People with neuromyelitis optica spectrum disorder (NMOSD) may experience gradual shrinkage, or atrophy, of the brain even during periods without relapses, according to a new study that challenges the long-held view that most neurological damage in NMOSD occurs mainly during relapses. The researchers also found that starting biologic therapies earlier…